drugset
drugset / Trial / NCT05887726

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

NCT05887726 ↗

Phase 2 Unknown 30 enrolled Liaoning Cancer Hospital & Institute
NaSingle-groupOpen-labelTreatment

Summary

This study is a prospective, open-label, single-arm phase II clinical study to evaluate the safety and efficacy of zanubrutinib plus R-CHOP (ZR-CHOP) as the first-line therapy for newly diagnosed diffuse large B-cell lymphoma patients with high-risk factors.

Timeline

Start
2023-08-01
Primary completion
2024-08-01
Completion
2025-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanubrutinib Small molecule 160 mg Oral
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Epirubicin Small molecule 75 mg/m2 Intravenous
Background Liposome Adriamycin Unknown 35 mg/m2 Intravenous
Background Prednisone Other / unclassified 100 mg Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background Vincristine Small molecule 1.4 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma